Literature DB >> 27940800

The Use of Systemic and Topical Fluoroquinolones.

Mary Anne Jackson, Gordon E Schutze.   

Abstract

Appropriate prescribing practices for fluoroquinolones, as well as all antimicrobial agents, are essential as evolving resistance patterns are considered, additional treatment indications are identified, and the toxicity profile of fluoroquinolones in children has become better defined. Earlier recommendations for systemic therapy remain; expanded uses of fluoroquinolones for the treatment of certain infections are outlined in this report. Prescribing clinicians should be aware of specific adverse reactions associated with fluoroquinolones, and their use in children should continue to be limited to the treatment of infections for which no safe and effective alternative exists or in situations in which oral fluoroquinolone treatment represents a reasonable alternative to parenteral antimicrobial therapy.
Copyright © 2016 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27940800     DOI: 10.1542/peds.2016-2706

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  26 in total

Review 1.  The Growing Threat of Antibiotic Resistance in Children.

Authors:  Rachel L Medernach; Latania K Logan
Journal:  Infect Dis Clin North Am       Date:  2018-03       Impact factor: 5.982

2.  Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections in Children: Translating Evidence From Adults Into Pediatric Practice.

Authors:  Rebecca G Same; Alice J Hsu; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2019-11-06       Impact factor: 3.164

3.  Safety of Quinolones in Children: A Systematic Review and Meta-Analysis.

Authors:  Siyu Li; Zhe Chen; Liang Huang; Zheng Liu; Yuqing Shi; Miao Zhang; Hailong Li; Linan Zeng; Jiaqi Ni; Yu Zhu; Zhi-Jun Jia; Guo Cheng; Lingli Zhang
Journal:  Paediatr Drugs       Date:  2022-06-30       Impact factor: 3.930

Review 4.  Mycoplasmas as Host Pantropic and Specific Pathogens: Clinical Implications, Gene Transfer, Virulence Factors, and Future Perspectives.

Authors:  Ali Dawood; Samah Attia Algharib; Gang Zhao; Tingting Zhu; Mingpu Qi; Kong Delai; Zhiyu Hao; Marawan A Marawan; Ihsanullah Shirani; Aizhen Guo
Journal:  Front Cell Infect Microbiol       Date:  2022-05-13       Impact factor: 6.073

5.  High Direct Bilirubin Associated With Levoffoxacin Use in a Neonate.

Authors:  Amy P Holmes; Charles E Hartis; Laurie J Rollins
Journal:  J Pediatr Pharmacol Ther       Date:  2020 Jan-Feb

6.  Fluoroquinolone Antibiotics and Tendon Injury in Adolescents.

Authors:  Rachael K Ross; Alan C Kinlaw; Mackenzie M Herzog; Michele Jonsson Funk; Jeffrey S Gerber
Journal:  Pediatrics       Date:  2021-05-14       Impact factor: 9.703

7.  Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List.

Authors:  Rachel S Meyers; Jennifer Thackray; Kelly L Matson; Christopher McPherson; Lisa Lubsch; Robert C Hellinga; David S Hoff
Journal:  J Pediatr Pharmacol Ther       Date:  2020

8.  A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders.

Authors:  Madalina Huruba; Andreea Farcas; Daniel Corneliu Leucuta; Camelia Bucsa; Mariana Sipos; Cristina Mogosan
Journal:  Sci Rep       Date:  2021-07-13       Impact factor: 4.379

9.  The AcrAB-TolC Efflux Pump Impacts Persistence and Resistance Development in Stationary-Phase Escherichia coli following Delafloxacin Treatment.

Authors:  Brandon A Byrd; Blesing Zenick; Maria C Rocha-Granados; Hanna E Englander; Patricia J Hare; Travis J LaGree; Angela M DeMarco; Wendy W K Mok
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

10.  Fluoroquinolone and no risk of Achilles-tendinopathy in childhood pneumonia under eight years of age-a nationwide retrospective cohort.

Authors:  Yunsun Kim; Gun Woo Park; Sangyoung Kim; Hui Jeong Moon; Sungho Won; Wankyo Chung; Hyeon-Jong Yang
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.